Newer opportunities in systemic therapy of lung cancer.
作者信息
Rajan A, Gutierrez M, Giaccone G
机构信息
National Cancer Institute, Bethesda, MD, USA.
出版信息
Ann Oncol. 2008 Sep;19 Suppl 7(Suppl 7):vii31-7. doi: 10.1093/annonc/mdn445.
Abstract
摘要
相似文献
1
Newer opportunities in systemic therapy of lung cancer.肺癌全身治疗的新机遇。
Ann Oncol. 2008 Sep;19 Suppl 7(Suppl 7):vii31-7. doi: 10.1093/annonc/mdn445.
2
Investigational agents in the management of non-small cell lung cancer.非小细胞肺癌治疗中的研究性药物
Curr Oncol Rep. 2009 Jul;11(4):275-84. doi: 10.1007/s11912-009-0039-x.
3
[Targeted therapies. New hopes, new challenges].[靶向治疗。新希望，新挑战]
Rev Mal Respir. 2008 Jun;25(6):661-2. doi: 10.1016/s0761-8425(08)73795-1.
4
Salvage with erlotinib plus bevacizumab: not in NSCLC.厄洛替尼联合贝伐单抗进行挽救治疗：不适用于非小细胞肺癌。
Lancet. 2011 May 28;377(9780):1810-2. doi: 10.1016/S0140-6736(11)60740-X.
5
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.在非小细胞肺癌治疗中联合抑制血管内皮生长因子和表皮生长因子信号传导
Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003.
6
Histology matters: individualizing treatment in non-small cell lung cancer.组织学很重要：个体化治疗非小细胞肺癌。
Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.
7
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.双重表皮生长因子受体（EGFR）抑制联合抗血管内皮生长因子（VEGF）治疗：一项非小细胞肺癌的I期临床试验
Oncotarget. 2013 Jan;4(1):118-27. doi: 10.18632/oncotarget.763.
8
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].[从2005年美国临床肿瘤学会（ASCO）和世界肺癌大会（WCLC）到临床实践：靶向治疗]
Rev Pneumol Clin. 2006 Feb;62 Spec no 1:1S30-4.
9
Medical treatment of non-small-cell lung cancer.非小细胞肺癌的医学治疗
Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721.
10
Targeting the epidermal growth factor receptor in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体的靶向治疗
Onkologie. 2010;33(12):704-9. doi: 10.1159/000322214. Epub 2010 Nov 26.
引用本文的文献
1
Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis.贝伐单抗在亚洲晚期非小细胞肺癌患者中的特定安全性概况：一项荟萃分析。
Medicine (Baltimore). 2015 Jun;94(24):e975. doi: 10.1097/MD.0000000000000975.
Zotero 插件